The role of nuclear factor kappa B in the pathogenesis of fetal growth restriction depending on vitamin D3 status

Authors

DOI:

https://doi.org/10.15574/HW.2025.4(179).4448

Keywords:

fetal growth restriction, placental dysfunction, NF‑κB p65, vitamin D₃, 25(OH)D, pregnancy

Abstract

Fetal growth restriction (FGR) is one of the most severe complications of pregnancy, associated with high perinatal morbidity and adverse long-term outcomes. Placental dysfunction plays a leading role in the pathogenesis of FGR and is accompanied by chronic inflammation and activation of NF‑κB-dependent signaling pathways. Growing evidence suggests that vitamin D3 deficiency contributes to the development of a proinflammatory placental phenotype.

Aim - to assess the relationship between vitamin D3 status and p65 NF‑κB activity in the placenta of pregnant women with fetal growth restriction.

Materials and methods. A total of 110 pregnant women were enrolled in the study: Group I (n=45) - FGR combined with vitamin D₃ deficiency (≤20 ng/mL); Group II (n=35) - FGR with an optimal vitamin D3 level (>30 ng/mL). The control group (n=30) included women with physiologic pregnancies and optimal vitamin D3 levels. Serum 25(OH)D concentrations were measured using enzyme-linked immunosorbent assay (ELISA). p65 NF‑κB activity in placental lysates was assessed by determining the ratio of phosphorylated to total p65 NF‑κB using ELISA. Statistical analysis was performed using parametric and nonparametric tests; was considered statistically significant.

Results. Women with FGR and vitamin D3 deficiency demonstrated the highest levels of NF‑κB activation: total p65 NF‑κB - 62.2 (60.7-64.2) pg/mL; phosphorylated p65 NF‑κB - 28.8 (24.8-32.1) pg/mL; p65 NF‑κB activity - 55.8 (54.1-57.2)%, which were significantly higher than those observed in the control group. In patients with FGR and optimal vitamin D3 levels, NF‑κB activation markers were significantly lower than in women with vitamin D3 deficiency (p<0.05), but remained higher than in controls.

Conclusions. Fetal growth restriction is associated with pronounced activation of NF‑κB-dependent proinflammatory signaling pathways in the placenta. Vitamin D3 deficiency markedly enhances p65 NF‑κB activation, promoting the development of a proinflammatory placental dysfunction phenotype. An optimal vitamin D3 level exerts a partial protective effect by limiting the intensity of the inflammatory response. The vitamin D₃/VDR ↔ NF‑κB p65 axis may represent a promising pathogenetic target for the prevention and reduction of FGR severity.

The study was performed in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Bioethics and Deontology Committee of the institution mentioned in the work. Informed consent of the patients was obtained for the research.

The authors declare no conflict of interest.

References

Ashley B, Simner C, Manousopoulou A, Jenkinson C, Hey F, Frost JM et al. (2022). Placental uptake and metabolism of 25(OH)vitamin D determine its activity within the fetoplacental unit. Elife. 11: e71094. https://doi.org/10.7554/eLife.71094; PMid:35256050 PMCid:PMC8903835

Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS, Roberts JM et al. (2010). Maternal serum 25-hydroxyvitamin D concentrations are associated with small-for-gestational age births in white women. J Nutr. 140(5): 999-1006. Epub 2010 Mar 3. https://doi.org/10.3945/jn.109.119636; PMid:20200114 PMCid:PMC2855265

Chen YH, Liu ZB, Ma L, Zhang ZC, Fu L, Yu Z et al. (2020). Gestational vitamin D deficiency causes placental insufficiency and fetal intrauterine growth restriction partially through inducing placental inflammation. J Steroid Biochem Mol Biol. 203: 105733. Epub 2020 Aug 9. https://doi.org/10.1016/j.jsbmb.2020.105733; PMid:32784046

Gerovasili E, Sarantaki A, Bothou A, Deltsidou A, Dimitrakopoulou A, Diamanti A. (2025). The role of vitamin D deficiency in placental dysfunction: A systematic review. Metabol Open. 25: 100350. https://doi.org/10.1016/j.metop.2025.100350; PMid:40034802 PMCid:PMC11874864

Gómez-Chávez F, Correa D, Navarrete-Meneses P, Cancino-Diaz JC, Cancino-Diaz ME, Rodríguez-Martínez S. (2021). NF-κB and Its Regulators During Pregnancy. Front Immunol. 12: 679106. Published 2021 May 5. https://doi.org/10.3389/fimmu.2021.679106; PMid:34025678 PMCid:PMC8131829

Korpysz A, Szalecki M. (2019). What's new in IUGR from the endocrinological point of view? Co nowego w IUGR w aspekcie endokrynologicznym? Pediatr Endocrinol Diabetes Metab. 25(4): 188-193. https://doi.org/10.5114/pedm.2019.91547; PMid:32270973

Mao D, Yuen LY, Ho CS, Wang CC, Tam CH, Chan MH. (2023). The Association of Prenatal Vitamin D Status With Pregnancy and Neonatal Outcomes. J Endocr Soc. 8(1): bvad142. https://doi.org/10.1210/jendso/bvad142; PMid:38075561 PMCid:PMC10701472

Motamed S, Anari R, Motamed S, Amani R. (2023). Vitamin D and biomarkers of inflammation and oxidative stress among pregnant women: a systematic review of observational studies. BMC Immunol. 24(1): 41. https://doi.org/10.1186/s12865-023-00577-w; PMid:37891486 PMCid:PMC10612223

Poladych I, Govsieiev D. (2025). The impact of vitamin D on the development of obstetric complications. Reproductive Health of Woman. 2 (2025): 8-13. https://doi.org/10.30841/2708-8731.2.2025.326493

Raia-Barjat T, Sarkis C, Rancon F, Thibaudin L, Gris JC, Alfaidy N et al. (2021). Vitamin D deficiency during late pregnancy mediates placenta-associated complications. Sci Rep. 11(1): 20708. https://doi.org/10.1038/s41598-021-00250-5; PMid:34671075 PMCid:PMC8528848

Published

2025-09-28